What does giant cell arteritis (GCA) mean in a neurological patient?

What GCA Means in a Neurological Patient

GCA (Giant Cell Arteritis) in a neurological patient represents a medical emergency requiring immediate recognition and treatment, as it is a systemic vasculitis that can cause devastating neurological complications including stroke, permanent vision loss, and death if untreated.

Definition and Clinical Significance

GCA is an immune-mediated systemic vasculitis affecting medium and large arteries, primarily the aorta and its branches, occurring almost exclusively in patients over age 50 1. In neurological contexts, GCA is particularly critical because:

• Cranial ischemic manifestations include visual and neurologic involvement such as amaurosis fugax, vision loss, and stroke 1
• Blindness and other ischemic complications occur almost exclusively before initiation of glucocorticoid therapy 2
• Stroke occurs in 3.3-7.2% of GCA patients, though intracranial vessel involvement is relatively rare 3, 4

Key Neurological Presentations

Most Common Neurological Features:

• Headache (present in 100% of cases in one series) - typically new-onset in patients ≥50 years 5
• Visual symptoms (73% with neuro-ophthalmic complications) 5:
  • Amaurosis fugax
  • Permanent vision loss
  • Diplopia
• Jaw claudication - pain while chewing due to masseter muscle ischemia 6, 7
• Tongue claudication and necrosis 7
• Scalp tenderness and necrosis 7

Severe Intracranial Complications:

• Cerebrovascular accidents involving 3, 4:
  • Intracranial internal carotid artery
  • Vertebrobasilar arteries
  • Posterior circulation strokes
• Intracranial aneurysms (rare but documented) 8
• Mortality in untreated intracranial GCA approaches 100%, and even with corticosteroid monotherapy reaches 58% 3

Critical Diagnostic Approach

Immediate Red Flags:

New-onset headache in patients aged ≥50 years with elevated ESR should prompt urgent evaluation for GCA 5. Do not delay treatment while awaiting diagnostic confirmation.

Diagnostic Testing Algorithm:

1. Temporal artery biopsy remains the primary diagnostic test 1:

   • Initially perform unilateral biopsy
   • Obtain long-segment specimen (>1 cm) 1
   • Must be performed within 2 weeks of starting glucocorticoids (preferably before treatment) 1
   • Sensitivity remains adequate up to 72 hours after starting steroids but drops significantly after 10 days 2

2. Noninvasive vascular imaging 1:

   • For negative temporal artery biopsy: obtain imaging of large vessels with clinical assessment 1
   • Baseline MR or CT angiography of neck/chest/abdomen/pelvis to detect large vessel involvement 1
   • Ultrasound with high-frequency probes (≥15 MHz for temporal arteries) 2
   • FDG-PET (sensitivity maintained if performed within 72 hours of starting 60 mg prednisone) 2

3. For intracranial involvement 4:

   • T1 black-blood post-gadolinium MRI shows vessel wall enhancement
   • MRA to evaluate intracranial vessels
   • Rapidly progressive bilateral ICA and vertebral artery lesions are characteristic

Treatment Protocol

Without Cranial Ischemia:

Initiate high-dose oral glucocorticoids (prednisone 1 mg/kg/day up to 80 mg) over IV pulse glucocorticoids 1. The routine use of IV pulse glucocorticoids carries increased infection risk that may outweigh benefits, especially in elderly patients 1.

With Threatened Vision Loss or Cranial Ischemia:

Initiate IV pulse glucocorticoids (methylprednisolone 500-1,000 mg/day for 3-5 days) followed by high-dose oral glucocorticoids 1. This population is at highest risk for permanent vision loss.

Adjunctive Therapy:

• Add tocilizumab to oral glucocorticoids (conditional recommendation over glucocorticoids alone) 1
• Add aspirin for patients with critical or flow-limiting involvement of vertebral or carotid arteries 1
• For intracranial GCA with severe involvement, consider adding immunosuppressants (mortality 40% with combined therapy vs 58% with steroids alone) 3

Dosing Schedule:

• Daily dosing over alternate-day schedule 1
• Taper glucocorticoids over weeks to months once disease control achieved 1

Critical Pitfalls to Avoid

1. Never delay treatment to obtain biopsy - blindness occurs before treatment initiation 2. Start steroids immediately if clinical suspicion is high.

2. Do not wait >72 hours after starting steroids to perform imaging - diagnostic sensitivity drops significantly 2.

3. Do not assume atherosclerosis in elderly patients with stroke - intracranial GCA can present with rapidly progressive bilateral vascular lesions that mimic atherothrombotic disease 4. T1 black-blood MRI with gadolinium helps distinguish GCA from atherosclerosis.

4. Do not rely solely on clinical remission - strongly recommend long-term clinical monitoring including 4-extremity blood pressures and inflammation markers 1.

5. Recognize that intracranial lesions can develop later than initial symptoms - headache may improve while vascular lesions progress 4.

Monitoring and Long-Term Management

• Clinical monitoring is mandatory even in apparent remission 1
• For isolated elevation of inflammation markers without symptoms: observe without escalating therapy 1
• Use MRA, CTA, or ultrasound for long-term monitoring of structural damage at sites of preceding inflammation 2
• Frequency of imaging should be individualized based on large vessel involvement 1

The key message: GCA in a neurological patient is a time-sensitive emergency where immediate high-dose glucocorticoid therapy can prevent irreversible blindness, stroke, and death 5, 3.